Join the DDA or

Emerade 300 microgram pens recall

Higher risk of activation failure

April 7th 2020

Tagged: MHRA alert

By MHRA

Emerade 300 microgram pens (Pharmaswiss Česka republika, an affiliate of Bausch & Lomb UK Limited) are being recalled due to a higher risk of activation failure.

The recall of Emerade 300 microgram auto-injectors from patients follows a previous alert for Emerade 150 microgram auto-injectors from patients. The alert notice provides GPs with a letter for affected patients.

Emerade 500 microgram auto-injectors are not being recalled.

Affected patients and carers should request a new prescription for an alternative brand. Quarantined or returned Emerade 300 microgram auto-injectors should be returned to suppliers.

The alert also contains information for managing requests during the COVID-19 pandemic.